Breast Cancer Screening Overdiagnosis Study
Analysis based on 8 articles · First reported Sep 14, 2026 · Last updated Sep 16, 2026
The study is unlikely to move broad equity markets, but it could influence sentiment around breast cancer screening volumes and related diagnostic and treatment markets. Lower perceived overdiagnosis may support continued or increased screening participation, modestly benefiting makers of mammography equipment and related healthcare providers.
A new meta-analysis published in the Journal of the National Cancer Institute concludes that overdiagnosis in breast cancer screening is far lower than previously estimated. Led by Sisse Helle Njor of the University of Southern Maine and Lillebaelt Hospital, the research team reanalyzed data from all eight major randomized controlled trials of mammography screening, including trials in New York, Malmo, Canada, Stockholm, Gothenburg, Edinburgh, the United Kingdom, and the Swedish Two-County study. The researchers compared trial patterns with real-world screening data from Denmark, where organized screening began in some regions about 17 years before others. Earlier estimates had suggested that 30 to 50 percent of breast cancers detected through screening might represent overdiagnosis. After accounting for factors such as control-group screening after trials ended, the number of screening rounds, and follow-up duration, the team found that the excess diagnoses in the trials closely matched the Danish pattern, where overdiagnosis is estimated below 5 percent. Co-authors Elsebeth Lynge of the University of Copenhagen and Matejka Rebolj of Queen Mary University of London emphasized that previous high estimates were based on immature trial data. The study was funded in part by the Novo Nordisk Foundation and Cancer Research UK. The findings may reassure women about screening benefits, though the researchers note the analysis reinterprets older trials rather than conducting a new randomized trial.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard